Patients
1-800-CEDARS-1
Search Menu Globe Arrow Right Close

Personal Statement

I am the director of the Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, at Cedars-Sinai and professor of medicine at Cedars-Sinai and the David Geffen School of Medicine at UCLA. I also hold the Eris M. Field Endowed Chair in Diabetes Research at Cedars-Sinai. I am both a diabetologist-endocrinologist and a molecular geneticist, and am head of the Endocrine Genetics Laboratory at Cedars-Sinai.

For the past 15 years, my research has included molecular biologic, genetic epidemiologic, epigenetic and clinical investigations in multiple ethnic groups, particularly Hispanic and non-Hispanic Caucasians. I have conducted extensive studies of the molecular genetics of insulin clearance and insulin resistance and related cardiovascular traits, and published the first report describing the high heritability of insulin clearance.

I currently serve as multi-principal investigator (PI) on the National Institutes of Health (NIH) R01, Improving Beta-Cell Function in Mexican American Women with Prediabetes; the NIH R01, Impact of the Gut Microbiome and Diet on Change in Insulin Homeostasis and Cardiometabolic Risk (MILES, Microbiome and Insulin Longitudinal Evaluation Study); and the NIH U01, Pathophysiology, Epidemiology and Prevention of Pancreatogenic Diabetes. The last study supports Cedars-Sinai participation in the Consortium for the Study of Pancreatitis, Diabetes, and Pancreatic Cancer-CPDPC.

I also lead the research program in polycystic ovary syndrome (PCOS) genetics at Cedars-Sinai, having served as the site PI of the study, Adrenal Androgen Excess in PCOS: Role of Genetics. I have also been involved in physiologic phenotyping of insulin-related traits. My lab established the insulin suppression test at Cedars-Sinai. I am the co-convener (with James Meigs) of the Cohorts for Heart and Aging Research in Genomic Epidemiology—CHARGE—Glycemia-Diabetes Working Group, an international consortium that assembled over 20 cohorts (comprising nearly 100,000 individuals) for the study of common and rare variants that contribute to glucose homeostasis and Type 2 diabetes. In these research activities, as well as in my role as division director, I serve as a mentor to postdoctoral fellows and junior faculty and am heavily involved in coordinating clinical and research training activities.

Contact the Goodarzi Lab

8700 Beverly Blvd.
Davis Building, Room 3008
Los Angeles, CA 90048